Mayo Clinic's Robotic Bronchoscopy Boosts Early Lung Cancer Detection by 85%

A new robotic-assisted bronchoscopy system is improving the detection of lung cancer with greater precision and safety. Developed by the Mayo Clinic, the technology combines AI pattern recognition, shape-sensing robotics, and mobile cone-beam CT to examine suspicious lung nodules. Early results show high accuracy in diagnosing malignant growths while keeping complications low. Lung cancer remains the deadliest form of cancer, with survival rates dropping sharply if detected late. When caught early, five-year survival reaches 67%, but this falls to just 12% once the disease spreads. In the US alone, around 1.6 million suspicious lung nodules are found each year through screening, though most turn out to be benign.

A five-year study by the Mayo Clinic tested robotic-assisted bronchoscopy alongside mobile cone-beam CT. The system achieved an 85% sensitivity rate in identifying malignant nodules and a diagnostic accuracy of nearly 77%. Of the lesions sampled, 56% were confirmed cancerous, 21% were benign, and 23% remained inconclusive under strict criteria. The procedure also proved safe, with complications in only 2.8% of cases. Beyond diagnosis, the robotic platform can now pair with treatments like pulsed electric field ablation (PEF), offering minimally invasive options. Integration with endobronchial ultrasound (EBUS) further improves staging by allowing lymph node biopsies. As of April 2026, adoption remains limited, with the Mayo Clinic and a handful of US and European centres leading early implementations. Wider use is still under evaluation through ongoing trials.

The robotic bronchoscopy system provides a clearer, safer way to detect lung cancer early. Its high accuracy and low complication rate could help more patients receive timely treatment. While still in early adoption, the technology may soon expand to more medical centres worldwide.